BTYNB 是 IMP1 结合 c-Myc mRNA 的有效选择性抑制剂, IC₅₀ 为 5 μM。BTYNB 对 IMP1 阳性的癌细胞株表现出选择性和有效性。BTYNB 可用于癌症研究。

BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA (IC 50 =5 μM). BTYNB exhibits selectivity and effectiveness against IMP1-postive cancer cell lines. BTYNB can be used for cancer research.

Solid

IC50: 5 μM (IMP1 c-Myc mRNA internation)

The oncofetal mRNA-binding protein, IMP1 binds to and stabilizes c-Myc, β-TrCP1, and other oncogenic mRNAs, it leads to increased expression of the proteins encoded by its target mRNAs.
BTYNB (10 uM; 0.5-1 hour) enhances the degradation rate of c-Myc mRNA in SK-MEL2 cells.
BTYNB (10-40 uM; 72 hours) degrades c-Myc expression in a dose-dependent manner in SK-MEL2 cells.
BTYNB (10-40 uM; 72 hours) decreases IMP1 expression in a dose-dependent manner in SK-MEL2 cells.
BTYNB (1-40 μM; 72 hours) decreases levels of CDC34, CALM1, β-TRCP1, and Col5A1 mRNAs expression in T47D/(A1-2) cells in the presence of hormone.
BTYNB elicits a robust dose-dependent inhibition of cell proliferation in IMP1-positive cells with IC50 of 2.3 μM, 3.6 μM, and 4.5 μM in ES-2, IGROV-1, and SK-MEL2 cells, respectively. BTYNB has no effects on IMP1-negative cells and demonstra

Room temperature in continental US; may vary elsewhere.

4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

[1]. Lily Mahapatra,et al. A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation. Transl Oncol

In Vitro: DMSO : 62.5 mg/mL (202.15 mM; Need ultrasonic)配制储备液